| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
178,600,000 |
| Market
Cap: |
291.12(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.8901 - $1.85 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 7.4 |
| Insider 3/6 Months : 8 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Precigen is a clinical-stage biopharmaceutical company improving gene and cell therapies. Co. is utilizing proprietary technology platforms to develop product candidates designed to diseases in its therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Co. is developing its clinical programs, including: PRGN-3005, PRGN-3006, and PRGN-3007, which are built on its UltraCAR-T platform; PRGN-2009 and PRGN-2012, which are based on its AdenoVerse immunotherapy platform; and AG019, which is built on its ActoBiotics platform. In addition, Co. has completed a Phase 1 study of INXN-4001, a non-viral triple-effector plasmid DNA, which is built on its UltraVector platform.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
96,686 |
1,592,031 |
13,134,243 |
| Total Buy Value |
$0 |
$136,327 |
$2,615,293 |
$22,822,494 |
| Total People Bought |
0 |
1 |
4 |
8 |
| Total Buy Transactions |
0 |
1 |
6 |
12 |
| Total Shares Sold |
0 |
96,686 |
455,706 |
505,706 |
| Total Sell Value |
$0 |
$136,327 |
$650,097 |
$765,097 |
| Total People Sold |
0 |
1 |
6 |
6 |
| Total Sell Transactions |
0 |
1 |
21 |
22 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Nimrodi Nir |
Chief Business Officer |
• – – |
2019-01-03 |
4 |
AS |
$7.07 |
$28,692 |
D/D |
(4,058) |
5,708 |
|
- |
|
| Lehr Donald P. |
Chief Legal Officer |
• – – |
2019-01-03 |
4 |
AS |
$7.07 |
$27,094 |
D/D |
(3,832) |
34,183 |
|
- |
|
| Perez Jeffrey Thomas |
SVP, IP Affairs |
• – – |
2019-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,766 |
22,303 |
|
- |
|
| Sterling Rick L. |
Chief Financial Officer |
• – – |
2019-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,766 |
84,387 |
|
- |
|
| Liffman Joel D |
SVP, Finance |
• – – |
2019-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,766 |
89,266 |
|
- |
|
| Sabzevari Helen |
President, Precigen, Inc. |
• – – |
2019-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,766 |
26,364 |
|
- |
|
| Walsh Robert F. Iii |
SVP, Energy & Fine Chem. |
• – – |
2019-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,766 |
9,766 |
|
- |
|
| Reed Thomas D. |
Chief Science Officer |
• – – |
2019-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,766 |
82,481 |
|
- |
|
| Bostick Thomas |
Chief Operating Officer |
• – – |
2019-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,766 |
10,046 |
|
- |
|
| Nimrodi Nir |
Chief Business Officer |
• – – |
2019-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,766 |
9,766 |
|
- |
|
| Lehr Donald P. |
Chief Legal Officer |
• – – |
2019-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,766 |
38,015 |
|
- |
|
| Reed Thomas D. |
Chief Science Officer |
• – – |
2018-12-31 |
4 |
S |
$6.36 |
$190,671 |
D/D |
(30,000) |
72,715 |
|
- |
|
| Kirk Randal J |
Chief Executive Officer |
• • • |
2018-12-31 |
4 |
A |
$6.54 |
$999,993 |
I/I |
127,082 |
16,043,868 |
|
- |
|
| Kirk Randal J |
Chief Executive Officer |
• • • |
2018-11-30 |
4 |
A |
$0.00 |
$0 |
I/I |
98,002 |
16,013,287 |
|
- |
|
| Kirk Randal J |
Chief Executive Officer |
• • • |
2018-11-20 |
4 |
A |
$0.00 |
$0 |
I/I |
396,668 |
83,221 |
|
- |
|
| Kirk Randal J |
Chief Executive Officer |
• • • |
2018-10-31 |
4 |
A |
$11.56 |
$999,992 |
I/I |
72,779 |
15,992,879 |
|
- |
|
| Liffman Joel D |
SVP, Finance |
• – – |
2018-10-15 |
4 |
AS |
$14.59 |
$1,152,808 |
D/D |
(79,000) |
79,500 |
|
- |
|
| Kirk Randal J |
Chief Executive Officer |
• • • |
2018-09-28 |
4 |
A |
$14.31 |
$999,979 |
I/I |
67,518 |
15,975,578 |
|
- |
|
| Kirk Randal J |
Chief Executive Officer |
• • • |
2018-08-31 |
4 |
A |
$13.74 |
$999,984 |
I/I |
71,227 |
15,963,964 |
|
- |
|
| Kirk Randal J |
Chief Executive Officer |
• • • |
2018-07-31 |
4 |
A |
$14.66 |
$999,982 |
I/I |
65,657 |
15,950,961 |
|
- |
|
| Sabzevari Helen |
President, Precigen, Inc. |
• – – |
2018-07-18 |
4 |
AS |
$14.54 |
$122,165 |
D/D |
(8,402) |
16,598 |
|
- |
|
| Sabzevari Helen |
President, Precigen, Inc. |
• – – |
2018-07-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,000 |
25,000 |
|
- |
|
| Kirk Randal J |
Chief Executive Officer |
• • • |
2018-07-03 |
4 |
B |
$13.37 |
$99,999,992 |
I/I |
7,479,431 |
15,937,319 |
2.64 |
- |
|
| Kirk Randal J |
Chief Executive Officer |
• • • |
2018-06-29 |
4 |
A |
$13.94 |
$999,987 |
I/I |
63,882 |
14,815,405 |
|
- |
|
| Kirk Randal J |
Chief Executive Officer |
• • • |
2018-05-31 |
4 |
A |
$16.20 |
$999,976 |
I/I |
61,444 |
14,801,058 |
|
- |
|
689 Records found
|
|
Page 20 of 28 |
|
|
0.07 (4.12%) 
